查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771646

美国气雾剂给药装置市场规模、份额、趋势分析报告（按类型、应用、分销管道、细分市场预测，2025-2030 年）

U.S. Aerosol Drug Delivery Devices Market Size, Share & Trends Analysis Report By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国气雾剂给药装置市场规模将达到 112.7 亿美元，2025 年至 2030 年的复合年增长率将达到 15.1%。

其背景是呼吸系统疾病的盛行率不断上升、吸入器技术的进步、医疗保健意识的不断增强以及家庭治疗需求的不断增长。根据美国肺臟协会的估计，到2022年，约有1,170万人（占美国成年人的4.6%）将被诊断出患有慢性阻塞性肺病（COPD），其中包括慢性支气管炎和肺气肿。

此外，世界卫生组织预测，到2030年，慢性阻塞性肺病、肺癌和结核病等危及生命的呼吸道疾病将占全球死亡人数的近五分之一。这些因素促使吸入器和雾化器等气雾剂装置的广泛使用。人们对家庭医疗保健的日益重视也促进了气雾剂给药装置的普及。

患者和医疗保健提供者都希望在家中舒适地接受治疗，从而减少去医院就诊的需要和相关的医疗费用。这种转变推动了对便携式、用户友好的气雾剂给药装置的需求，这些装置有助于呼吸系统疾病的自我管理。电子商务平台和线上药局的普及进一步提高了此类设备的可近性。

气雾剂给药装置的技术进步将显着推动市场成长。配备感测器的智慧吸入器可监测药物使用情况并提高服药依从性，正日益普及。技术创新包括双腔直吸式吸入器 (DPI)、呼吸驱动定量吸入器 (MDI) 和环保推进剂。这些技术提高了药物传输效率并方便了患者使用。例如，Aerogen 的振动筛孔式喷雾器技术现已在美国医院广泛采用，它就是一项创新，旨在改善机械通气和非机械通气患者的治疗。这些进步使这些设备使用起来更简单、更实用，从而促进了患者和医疗保健提供者的采用。

新冠疫情对美国市场产生了正面影响。新冠疫情及其相关呼吸系统疾病的增多，尤其影响到需要持续呼吸照护的气喘和慢性阻塞性肺病患者，导致吸入器和雾化器的需求激增。家庭医疗保健和远端医疗的转变推动了携带式和智慧吸入设备的普及。然而，疫情扰乱了供应链，导致原材料短缺和生产延误，暂时抑制了市场成长。此外，由于医院优先考虑重症监护，非紧急呼吸护理和手术数量有所下降。儘管存在这些挫折，但这场危机加速了数位医疗领域的创新，为美国市场的长期前景提供了支撑。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场趋势与展望
  • 目前可用的气雾剂药物的配方和成本分析。
  • 定价分析
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国气雾剂给药装置市场分析工具：PESTEL
    • 政治与法律
    • 经济与社会
    • 科技
  • 美国气雾剂给药装置市场分析工具：波特五力分析

第四章美国气雾剂给药装置市场：类型估计与趋势分析

  • 美国气雾剂给药装置市场：类型变化分析
  • 美国气雾剂给药装置市场：细分仪表板
  • 2024 年和 2030 年类型趋势和市场占有率分析
  • 按类型
  • 吸入器
    • 加压定量吸入器（pMDI）
    • 干粉吸入器（DPI）
  • 喷雾器
    • 喷射
    • 网
    • 超音波

第五章美国气雾剂给药装置市场：应用评估与趋势分析

  • 美国气雾剂给药装置市场：应用趋势分析
  • 美国气雾剂给药装置市场：应用细分仪表板
  • 2024 年和 2030 年应用趋势和市场占有率分析
  • 按用途
  • COPD
  • 气喘
  • 囊肿纤维化
  • 其他（肺动脉高压（PAH）等）

第六章美国气雾剂给药装置市场：通路评估与趋势分析

  • 美国气雾剂给药装置市场：通路差异分析
  • 美国气雾剂给药装置市场：分销通路细分仪表板
  • 2024 年和 2030 年分销通路趋势和市场占有率分析
  • 按分销管道
  • 零售药局
  • 网路药局
  • 设施药房

第七章 竞争态势

  • 公司分类
  • 2024年企业市场地位/份额分析
  • Company Share Analysis
  • 公司简介/上市公司
    • AptarGroup, Inc.
    • Koninklijke Philips NV
    • AstraZeneca
    • Novartis AG
    • Sanofi
    • OMRON Corporation
    • Medline Industries, LP.
    • GF Health Products, Inc.
    • DRIVE MEDICAL GMBH &CO. KG
    • Teva Pharmaceutical Industries Ltd.
    • Aerogen（Stamford Devices Limited Group）
    • Sensirion AG
    • PARI Respiratory Equipment, Inc.
    • Catalent, Inc.
    • Pfizer Inc.
    • Beurer GmbH
Product Code: GVR-4-68040-615-4

Market Size & Trends:

The U.S. aerosol drug delivery devices market size was estimated at USD 11.27 billion in 2024 and is expected to grow at a CAGR of 15.1% from 2025 to 2030. This is attributed to the rising prevalence of respiratory diseases, advancements in inhaler technology, increasing healthcare awareness, and the growing demand for home-based treatments. According to estimates from the American Lung Association, in 2022, approximately 11.7 million people, or 4.6% of adults, were diagnosed with COPD, including chronic bronchitis and emphysema.

In addition, the WHO projects that by 2030, life-threatening respiratory diseases such as COPD, lung cancer, and tuberculosis will be responsible for nearly one in five deaths worldwide. Such factors contribute to the widespread adoption of aerosol devices, including inhalers and nebulizers. The growing emphasis on home healthcare contributes to the increased adoption of aerosol drug delivery devices.

Patients and healthcare providers are seeking treatments administered in the comfort of home, reducing the need for hospital visits and associated healthcare costs. This shift drives demand for portable, user-friendly aerosol delivery devices that facilitate self-management of respiratory conditions. The availability of e-commerce platforms and online pharmacies has further enhanced accessibility to these devices.

Technological advancements in aerosol drug delivery devices significantly propel market growth. Smart inhalers with sensors to monitor medication usage and improve adherence are becoming increasingly prevalent. Innovations include dual-chamber DPIs, breath-actuated MDIs, and environmentally friendly propellants. These technologies enhance drug delivery efficiency and patient convenience. For instance, Aerogen's vibrating mesh nebulizer technology, now widely adopted in U.S. hospitals, exemplifies innovation in improving treatment for ventilated and non-ventilated patients. Such advancements make devices more straightforward and practical, encouraging patient and healthcare provider adoption.

The COVID-19 pandemic had a positive impact on the U.S. market. The demand for inhalers and nebulizers surged as COVID-19 and related respiratory conditions increased, particularly affecting patients with asthma and COPD who required ongoing respiratory care. The shift toward at-home healthcare and telemedicine drove the adoption of portable and smart inhalation devices. However, the pandemic disrupted supply chains, leading to raw material shortages and production delays, temporarily constraining market growth. In addition, hospitals prioritized critical COVID-19 care, causing a decline in non-urgent respiratory treatments and procedures. Despite these setbacks, the crisis accelerated digital health innovation and supported the long-term outlook of the U.S. market.

U.S. Aerosol Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aerosol drug delivery devices market report based on type, application, and distribution channel:

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Inhaler
    • Pressurized Metered-Dose Inhaler (pMDI)
    • Dry-Powder Inhaler (DPI)
  • Nebulizer
    • Jet
    • Mesh
    • Active
    • Passive
    • Ultrasonic
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • COPD
  • Asthma
  • Cystic Fibrosis
  • Other (Pulmonary Arterial Hypertension (PAH), etc.)
  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Retail Pharmacies
  • Online Pharmacies
  • Institutional Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Aerosol Drug Delivery Devices Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Type segment outlook
      • 2.1.2.2. Application segment outlook
      • 2.1.2.3. Distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Currently Available Aerosol Drug Formulations and Cost Analysis
  • 3.4. Pricing Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Rising prevalence of respiratory diseases
      • 3.5.1.2. Technological advancements
      • 3.5.1.3. Rising geriatric population
      • 3.5.1.4. Increasing awareness of self-medication and home healthcare
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. High cost of devices
    • 3.5.3. Market Opportunity Analysis
    • 3.5.4. Market Challenges Analysis
  • 3.6. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: PESTEL
    • 3.6.1. Political & Legal
    • 3.6.2. Economic & Social
    • 3.6.3. Technology
  • 3.7. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: Porter's

Chapter 4. U.S. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Aerosol Drug Delivery Devices Market: Type Movement Analysis
  • 4.2. U.S. Aerosol Drug Delivery Devices Market: Type Segment Dashboard
  • 4.3. Type Movement & Market Share Analysis, 2024 & 2030
  • 4.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Type
  • 4.5. Inhaler
    • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.2. Pressurized Metered-Dose Inhaler (pMDI)
      • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Dry-Powder Inhaler (DPI)
      • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6. Nebulizer
    • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.2. Jet
      • 4.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3. Mesh
      • 4.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
      • 4.6.3.2. Active
        • 4.6.3.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
      • 4.6.3.3. Passive
        • 4.6.3.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.4. Ultrasonic
      • 4.6.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Aerosol Drug Delivery Devices Market: Application Movement Analysis
  • 5.2. U.S. Aerosol Drug Delivery Devices Market: Application Segment Dashboard
  • 5.3. Application Movement & Market Share Analysis, 2024 & 2030
  • 5.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Application
  • 5.5. COPD
    • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.6. Asthma
    • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.7. Cystic Fibrosis
    • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.8. Other (Pulmonary Arterial Hypertension (PAH), etc.)
    • 5.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Movement Analysis
  • 6.2. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Segment Dashboard
  • 6.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2030
  • 6.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Distribution Channel
  • 6.5. Retail Pharmacies
    • 6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.7. Institutional Pharmacies
    • 6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position/Share Analysis, 2024
  • 7.3. Company Share Analysis
  • 7.4. Company Profiles/Listing
    • 7.4.1. AptarGroup, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments
    • 7.4.2. Koninklijke Philips N.V.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments
    • 7.4.3. AstraZeneca
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments
    • 7.4.4. Novartis AG
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments
    • 7.4.5. Sanofi
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments
    • 7.4.6. OMRON Corporation
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments
    • 7.4.7. Medline Industries, LP.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments
    • 7.4.8. GF Health Products, Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments
    • 7.4.9. DRIVE MEDICAL GMBH & CO. KG
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments
    • 7.4.10. Teva Pharmaceutical Industries Ltd.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments
    • 7.4.11. Aerogen (Stamford Devices Limited Group)
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments
    • 7.4.12. Sensirion AG
      • 7.4.12.1. Participant's Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Recent Developments
    • 7.4.13. PARI Respiratory Equipment, Inc.
      • 7.4.13.1. Participant's Overview
      • 7.4.13.2. Financial Performance
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Recent Developments
    • 7.4.14. Catalent, Inc.
      • 7.4.14.1. Participant's Overview
      • 7.4.14.2. Financial Performance
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Recent Developments
    • 7.4.15. Pfizer Inc.
      • 7.4.15.1. Participant's Overview
      • 7.4.15.2. Financial Performance
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Recent Developments
    • 7.4.16. Beurer GmbH
      • 7.4.16.1. Participant's Overview
      • 7.4.16.2. Financial Performance
      • 7.4.16.3. Product Benchmarking
      • 7.4.16.4. Recent Developments

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. aerosol drug delivery devices market revenue estimates and forecast, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. aerosol drug delivery devices market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. aerosol drug delivery devices market revenue estimates and forecast, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 US Aerosol Drug Delivery Devices Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for Market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Type segment outlook
  • Fig. 11 Application segment outlook
  • Fig. 12 Distribution Channel segment outlook
  • Fig. 13 Competitive landscape
  • Fig. 14 US Aerosol Drug Delivery Devices Market: Market dynamics
  • Fig. 15 US Aerosol Drug Delivery Devices Market: Porter's analysis
  • Fig. 16 US Aerosol Drug Delivery Devices Market: PESTLE analysis
  • Fig. 17 US Aerosol Drug Delivery Devices Market: Type segment dashboard
  • Fig. 18 US Aerosol Drug Delivery Devices Market: Type movement share analysis
  • Fig. 19 Inhaler Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Pressurized Metered-Dose Inhaler (PDMI) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Dry-Powder Inhaler (DPI) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Nebulizers Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Jet Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Mesh Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Active Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Passive Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Ultrasonic Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 US Aerosol Drug Delivery Devices Market: Application segment dashboard
  • Fig. 29 US Aerosol Drug Delivery Devices Market: Application Movement Share Analysis
  • Fig. 30 Asthma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Chronic Obstructive Pulmonary Disease (COPD) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Cystic Fibrosis Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Other (Pulmonary Arterial Hypertension (PAH), etc) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 US Aerosol Drug Delivery Devices Market: Distribution Channel Segment Dashboard
  • Fig. 35 US Aerosol Drug Delivery Devices Market: Distribution Channel Movement Share Analysis
  • Fig. 36 Retail Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Institutional Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Online Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Company categorization
  • Fig. 40 Company Market position analysis, 2024
  • Fig. 41 Strategic framework